Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
暂无分享,去创建一个
Nicholas Lange | Pinchen Yang | N. Lange | H. Lane | G. Tsai | M. Chong | Pinchen Yang | Hsien-Yuan Lane | Guochuan Tsai | Mian-Yoon Chong
[1] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.
[2] Michael V. Johnston,et al. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development , 1990, Brain Research Reviews.
[3] U. Ahlfors,et al. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.
[4] J. Coyle,et al. Modulation of N-methyl-D-aspartate receptor function by glycine transport. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[6] P. Blache,et al. Molecular cloning and tissue distribution of rat sarcosine dehydrogenase. , 1998, European journal of biochemistry.
[7] R. Dingledine,et al. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. , 1989, Molecular pharmacology.
[8] J. Coyle,et al. Glutamatergic mechanisms in schizophrenia. , 2003, Annual review of pharmacology and toxicology.
[9] L. Ryan,et al. ASSESSING NORMALITY IN RANDOM EFFECTS MODELS , 1989 .
[10] T. Branchek,et al. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors , 1992, Neuron.
[11] J. Coyle,et al. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia , 1998, Biological Psychiatry.
[12] I. Galve-Roperh,et al. Direct Calcium Binding Results in Activation of Brain Serine Racemase* , 2002, The Journal of Biological Chemistry.
[13] D. Javitt,et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.
[14] J. Lindenmayer,et al. Five‐Factor Model of Schizophrenia Initial Validation , 1994, The Journal of nervous and mental disease.
[15] J. Olney,et al. Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.
[16] D. Javitt,et al. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. , 1996, Psychopharmacology bulletin.
[17] H. Levy,et al. Massachusetts metabolic disorders screening program , 1973 .
[18] M. Eschenbrenner,et al. Cloning and mapping of the cDNA for human sarcosine dehydrogenase, a flavoenzyme defective in patients with sarcosinemia. , 1999, Genomics.
[19] D. Javitt,et al. Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia , 1996, British Journal of Psychiatry.
[20] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[21] A. Thomson,et al. Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices , 1989, Nature.
[22] J. Newcomer,et al. Glycine agonists: what can they teach us about schizophrenia? , 1999, Archives of general psychiatry.
[23] H. Westenberg,et al. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients , 1996, Biological Psychiatry.
[24] G. Simpson,et al. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.
[25] Nicholas Lange,et al. D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.
[26] T. Gordh,et al. The NMDA-receptor antagonist CPP abolishes neurogenic ‘wind-up pain’ after intrathecal administration in humans , 1992, Pain.
[27] D. Javitt,et al. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. , 2002, The American journal of psychiatry.
[28] D. Javitt,et al. Adjunctive high-dose glycine in the treatment of schizophrenia. , 2001, The international journal of neuropsychopharmacology.
[29] A. Halberstadt. The phencyclidine-glutamate model of schizophrenia. , 1995, Clinical neuropharmacology.
[30] C. Harding,et al. sar: a genetic mouse model for human sarcosinemia generated by ethylnitrosourea mutagenesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[31] T. Barnes. A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.
[32] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[33] J. Coyle,et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. , 1999, Archives of general psychiatry.
[34] Charles R. Yang,et al. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. , 2003, Journal of neurophysiology.
[35] A. Lajtha,et al. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors , 1999, Biological Psychiatry.
[36] P. Herrling,et al. d-CPPene (SDZ EAA-494)—A Competitive NMDA Antagonist: Pharmacology and Results in Humans , 1997 .